Subtopic Deep Dive
Anti-TNF Therapy in Crohn's Disease
Research Guide
What is Anti-TNF Therapy in Crohn's Disease?
Anti-TNF therapy in Crohn's disease uses tumor necrosis factor inhibitors like infliximab and adalimumab for induction and maintenance of remission in moderate-to-severe cases.
Infliximab combined with azathioprine achieved higher corticosteroid-free remission rates than monotherapy in moderate-to-severe Crohn's disease (Colombel et al., 2010, 3058 citations). Infliximab effectively treats fistulizing Crohn's disease (Present et al., 1999, 2720 citations). European consensus guidelines outline management strategies including anti-TNF dosing and monitoring (Dignass et al., 2010, 1487 citations).
Why It Matters
Anti-TNF agents like infliximab improved fistula closure rates from 13% with placebo to 68% in Crohn's patients (Present et al., 1999). Combination therapy with azathioprine reduced clinical remission failure at week 26 to 30% versus 54% for azathioprine alone (Colombel et al., 2010). ECCO guidelines recommend therapeutic drug monitoring to optimize dosing and manage loss of response (Torres et al., 2019). These advances shifted Crohn's from surgery-dependent to medically managed disease.
Key Research Challenges
Primary Non-Response Prediction
Up to 30% of Crohn's patients fail initial anti-TNF induction due to unpredictable factors. Colombel et al. (2010) showed infliximab efficacy varies by baseline severity. Serological markers aid phenotyping but lack precision (Silverberg et al., 2005).
Secondary Loss of Response
Antibody formation against infliximab causes 20-40% annual loss of response. Dose intensification or switching agents is common but suboptimal. Consensus stresses monitoring (Dignass et al., 2010).
Optimal Combination Regimens
Infliximab plus azathioprine outperforms monotherapy but raises infection risks. Long-term safety data remain limited (Colombel et al., 2010). ECCO guidelines balance efficacy and risks (Torres et al., 2019).
Essential Papers
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg, Jack Satsangi, Tariq Ahmad et al. · 2005 · Canadian Journal of Gastroenterology · 3.3K citations
The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classificati...
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · 2010 · New England Journal of Medicine · 3.1K citations
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or infliximab monotherapy were more likely to have a corticosteroid-free clinical remission than ...
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · 2013 · New England Journal of Medicine · 2.8K citations
Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI Clinica...
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · 1999 · New England Journal of Medicine · 2.7K citations
Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease.
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes, Corinne Gower‐Rousseau, Philippe Seksik et al. · 2011 · Gastroenterology · 2.1K citations
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Axel Dignaß, Gert Van Assche, James O. Lindsay et al. · 2010 · Journal of Crohn s and Colitis · 1.5K citations
This paper is the second in a series of three publications relating to the European evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the management of active...
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche, Axel Dignaß, Julián Panés et al. · 2010 · Journal of Crohn s and Colitis · 1.5K citations
peer reviewed
Reading Guide
Foundational Papers
Start with Present et al. (1999) for infliximab's fistula proof-of-concept, then Colombel et al. (2010) for combination therapy evidence establishing modern standards.
Recent Advances
Torres et al. (2019) updates ECCO therapeutics; Silverberg et al. (2005) enables phenotype-guided anti-TNF use.
Core Methods
Induction/maintenance dosing, therapeutic drug monitoring, combo immunomodulators (Colombel et al., 2010; Dignass et al., 2010).
How PapersFlow Helps You Research Anti-TNF Therapy in Crohn's Disease
Discover & Search
Research Agent uses searchPapers for 'infliximab Crohn\'s disease combination therapy' retrieving Colombel et al. (2010), then citationGraph reveals 3058 forward citations including Torres et al. (2019), and findSimilarPapers identifies related fistula trials like Present et al. (1999).
Analyze & Verify
Analysis Agent applies readPaperContent to extract remission rates from Colombel et al. (2010), verifyResponse with CoVe cross-checks claims against Silverberg et al. (2005) phenotyping data, and runPythonAnalysis computes meta-analysis odds ratios from trial endpoints with GRADE grading for evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in loss-of-response predictors between Dignass et al. (2010) and recent ECCO updates, flags contradictions in monotherapy efficacy; Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 10+ references, latexCompile for review drafts, and exportMermaid for treatment algorithm diagrams.
Use Cases
"Analyze remission rates in infliximab vs combination therapy trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of Colombel et al. 2010 endpoints) → GRADE-graded odds ratios table with p-values.
"Draft LaTeX review on anti-TNF dosing for fistulizing Crohn's"
Research Agent → citationGraph (Present et al. 1999) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → camera-ready PDF with figures.
"Find code for anti-TNF pharmacokinetic modeling"
Research Agent → exaSearch 'anti-TNF Crohn\'s PK model' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runnable Python sandbox simulation.
Automated Workflows
Deep Research workflow scans 50+ anti-TNF papers via searchPapers → citationGraph → structured report on induction regimens citing Colombel et al. (2010). DeepScan applies 7-step CoVe to verify loss-of-response rates from Dignass et al. (2010) with statistical checkpoints. Theorizer generates hypotheses on serological predictors from Silverberg et al. (2005) integrated with Present et al. (1999).
Frequently Asked Questions
What defines anti-TNF therapy in Crohn's?
Anti-TNF therapy inhibits TNF-alpha using monoclonal antibodies like infliximab for induction (5 mg/kg weeks 0,2,6) and maintenance in moderate-severe Crohn's (Present et al., 1999; Colombel et al., 2010).
What are key methods for response optimization?
Therapeutic drug monitoring and combination with azathioprine improve outcomes; infliximab monotherapy yields 45% remission vs 60% combined at week 26 (Colombel et al., 2010).
What are seminal papers?
Colombel et al. (2010, 3058 citations) proves combination superiority; Present et al. (1999, 2720 citations) establishes fistula efficacy; Dignass et al. (2010, 1487 citations) provides consensus management.
What open problems persist?
Predicting primary non-response and managing immunogenicity without excessive dosing; ECCO calls for personalized strategies (Torres et al., 2019).
Research Inflammatory Bowel Disease with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Anti-TNF Therapy in Crohn's Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Inflammatory Bowel Disease Research Guide